Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 Vaccine for Recurrent High Grade Glioma
NCT00293423Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Nov 2005
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vitespen in high-grade glioma (HGG), sponsored by University of California, San Francisco. Started Nov 2005; status: completed.
02
Drugs
vitespen
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00293423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293423.